Please upgrade your browser.
The May meeting of the Kidney Cancer Association was held a the Venice Health Park Lions room on May the 27th.
The Cato Institute invites you to participate in a one-day conference, featuring health care experts from across the political landscape, on the state and future of health care reform in America. Even before the results of the 2008 elections were known, lawmakers in Washington, D.C., were preparing some of the most sweeping health care reforms America has seen in decades.
Congress is poised to pass one of the worst public health laws ever conceived. John E. Calfee calls the House-passed version one of the worst public health laws ever conceived.
Though President Obama and Democratic leaders in Congress would like to pass a national health care bill by September, the passage of such a bill faces a number of obstacles. Among these hurdles are how to raise revenue to pay for health care reform, a lack of public passion about health care as a policy priority, and the fact that young voters are largely unconcerned with health insurance.
Find out how a class of fifth graders showed their support for people affected by kidney cancer and the Lift for Life team.
A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the INTORACT (Investigation of TORISEL And bevacizumab Combination Therapy) study, a worldwide randomized, open-label, phase 3b study comparing TORISEL(R) (temsirolimus) plus Avastin(R) (bevacizumab) versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC). Wyeth Research is conducting the INTORACT study with the support and assistance of Roche and Genentech.
Democrats rank health reform second from the top, Republicans second from the bottom. Independents, whose ranks have swelled since the election, place it fifth.
Stuart had been fighting kidney cancer and a scan showed that the drug had slowed down the growth of his tumour.
The problem is the new board, the Federal Coordinating Council for Comparative Effectiveness Research, already has been appointed by the federal government and it is composed entirely of government employees.
|Powered by NeonCRM|